[PS1] Presidential Session 1
【E】

[PS1-4] A randomized phase 3 study of nintedanib with chemotherapy vs. chemotherapy alone for advanced NSCLC with IPF (J-SONIC)

^○Kohei Otsubo^1,2, Junji Kishimoto³, Masahiko Ando⁴, Hirotsugu Kenmotsu⁵, Yuji Minegishi^6,7, Hidehito Horinouchi⁸, Terufumi Kato⁹, Eiki Ichihara¹⁰, Masashi Kondo¹¹, Shinji Atagi¹², Motohiro Tamiya¹³, Satoshi Ikeda¹⁴, Toshiyuki Harada¹⁵, Shinnosuke Takemoto¹⁶, Hidetoshi Hayashi¹⁷, Nobuyuki Yamamoto¹⁸, Kazuhiko Nakagawa¹⁷, Yoichi Nakanishi^2,19, Isamu Okamoto² (1.Department of Respiratory Medicine, Kitakyushu Municipal Medical Center, 2.Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University, 3.Department of Research and Development of Next Generation Medicine, Faculty of Medical Sciences, Kyushu University, 4.Department of Advanced Medicine, Nagoya University Hospital, 5.Division of Thoracic Oncology, Shizuoka Cancer Center, 6.Division of Pulmonary Medicine, Infectious Disease, and Oncology, Department of Internal Medicine, Nippon Medical School, 7.Department of Respiratory Medicine, Mitsui Memorial Hospital, 8.Department of Thoracic Oncology, National Cancer Center Hospital, 9.Department of Thoracic Oncology, Kanagawa Cancer Center, 10.Department of Allergy and Respiratory Medicine, Okayama University Hospital, 11.Department of Respiratory Medicine, Fujita Health University School of Medicine, 12.Department of Thoracic Oncology, National Hospital Organization Kinki-chuo Chest Medical Center, 13.Department of Thoracic Oncology, Osaka International Cancer Institute, 14.Department of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, 15.Department of Respiratory Medicine, JCHO Hokkaido Hospital, 16.Department of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, 17.Department of Medical Oncology, Kindai University Faculty of Medicine, 18.Internal Medicine III, Wakayama Medical University, 19.Kitakyushu City Hospital Organization)